APOB and obesity due to melanocortin 4 receptor deficiency: In 2019, the ESC/EAS Guidelines [5] recommended that, when evaluating patients with diabetes, metabolic syndrome, obesity, high triglyceride concentration or very low LDL-c levels, non-HDL and ApoB could be preferred in order to estimate CV risk.